AU2002351693A1 - Use of a kmo inhibitor for producing a pharmaceutical composition - Google Patents

Use of a kmo inhibitor for producing a pharmaceutical composition

Info

Publication number
AU2002351693A1
AU2002351693A1 AU2002351693A AU2002351693A AU2002351693A1 AU 2002351693 A1 AU2002351693 A1 AU 2002351693A1 AU 2002351693 A AU2002351693 A AU 2002351693A AU 2002351693 A AU2002351693 A AU 2002351693A AU 2002351693 A1 AU2002351693 A1 AU 2002351693A1
Authority
AU
Australia
Prior art keywords
producing
pharmaceutical composition
kmo inhibitor
kmo
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002351693A
Inventor
Edgar Dahl
Esmeralda Heiden Castanos-Velez
Andreas Rump
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metagen Pharmaceuticals GmbH
Original Assignee
Metagen Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagen Pharmaceuticals GmbH filed Critical Metagen Pharmaceuticals GmbH
Publication of AU2002351693A1 publication Critical patent/AU2002351693A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU2002351693A 2001-11-28 2002-11-20 Use of a kmo inhibitor for producing a pharmaceutical composition Abandoned AU2002351693A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10159215A DE10159215A1 (en) 2001-11-28 2001-11-28 Use of a KMO inhibitor for the manufacture of a pharmaceutical composition
DE10159215.9 2001-11-28
PCT/DE2002/004309 WO2003047571A2 (en) 2001-11-28 2002-11-20 Use of a kmo inhibitor for producing a pharmaceutical composition

Publications (1)

Publication Number Publication Date
AU2002351693A1 true AU2002351693A1 (en) 2003-06-17

Family

ID=7707802

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002351693A Abandoned AU2002351693A1 (en) 2001-11-28 2002-11-20 Use of a kmo inhibitor for producing a pharmaceutical composition

Country Status (3)

Country Link
AU (1) AU2002351693A1 (en)
DE (1) DE10159215A1 (en)
WO (1) WO2003047571A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201211120D0 (en) * 2012-06-22 2012-08-01 Bessede Alban Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
GB201322538D0 (en) 2013-06-21 2014-02-05 Immusmol Sas Method for detecting small molecules in a sample
WO2016193499A1 (en) * 2015-06-05 2016-12-08 Immusmol Sas Immunomodulatory antibody or immunotherapeutic, agent which increases and/or mimicks kynurenine, and optional combination thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689327A5 (en) * 1995-01-23 1999-02-26 Josef Waller Pharmaceutical preparation for cancer treatment
US5916906A (en) * 1995-03-14 1999-06-29 Shaskan; Edward G. Compositions comprising nicotinylalanine and an inhibitor of glycine conjugation or vitamin B6

Also Published As

Publication number Publication date
DE10159215A1 (en) 2003-06-12
WO2003047571A2 (en) 2003-06-12
WO2003047571A3 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
HK1064035A1 (en) Pharmaceutical salts of 1-phenyl-3-dimethylamino-propane compounds
AU2003276549A1 (en) Pharmaceutical compositions containing a biguanide-glitazone combination
AU2003226189A1 (en) Oral administration of epothilones
AU2002361149A1 (en) Set of teeth
AU2002353366A1 (en) The process of manufacturing a pharmaceutical composition useful for management of cancer
AUPR409401A0 (en) Analgesic compound
WO2004080461A3 (en) Stable pharmaceutical compositions of desloratadine
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
PL369268A1 (en) A stable pharmaceutical composition of pravastatin
AU2002244865A1 (en) Pharmaceutical composition of ibuprofen
AU2002351693A1 (en) Use of a kmo inhibitor for producing a pharmaceutical composition
AU2003265373A1 (en) Preparation of aztreonam
AU2003284786A1 (en) Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
AU2003208621A1 (en) A pharmaceutical composition
AU2003263480A1 (en) Oral pharmaceutical compositions of fenofibrate having high bioavailability
AU2002308986A1 (en) Process for preparation of a quinolinecarbaldehyde
AU2002305868A1 (en) Inhibitors of reggamma
AU2002342940A1 (en) New pharmaceutical compounds
AU2003287388A1 (en) Inhibition of hiv-1 replication
AU2003276994A1 (en) Use of ribavirin for producing a pharmaceutical composition directed against bunyaviridae
AU2002333193A1 (en) A pharmaceutical composition for dermal application
AU2002258749A1 (en) Inhibitors of glycosaminoglycans
AU2003237157A1 (en) Preparation of phosphatase inhibitors
AU2003242538A1 (en) Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
AU2002351722A1 (en) A pharmaceutical composition for dermal application

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase